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Paper IV of the present series reviewed the mechanism by which helenine, an 
antibiotictike substance derived from Penicilliura funiculosum,  exerts its anti- 
viral effect. It was concluded that helenine is not directly virucidal but exerts 
its effect through mobifization of host factor(s) (1).  This conclusion was based 
on the observation that protection of mice against Semliki Forest virus challenge 
was not evident until 6 to 48 hr after the administration of helenine; injection of 
helenine at the time of, or shortly after infection, had tittle or no protective 
effect. A similar period of pretreatment was necessary for helenine to inhibit the 
cytopathogenic effect of Semliki Forest virus in chick embryo fibroblast cell 
culture (2).  Moreover, animals which survived a  viral challenge because pre- 
treated with helenine proved fully susceptible when rechallenged with the same 
agent,  a  fact perhaps indicative of interference with replication of complete, 
antigenically potent virions, capable of eticiting acquired immunity. Thus the 
protective activity of helenine is analogous to that observed with viral inter- 
ference,  an  antiviral  effect mediated  by interferon  (3,  4).  Interferon is  not 
demonstrable in normal cells but appears after a characteristic lag period sev- 
eral hours after its induction, at which time  cellular resistance to virus is apparent 
(5).  Furthermore, interferon exerts its effect in the viral replication cycle prior 
to assembly of complete viral particles, thereby inhibiting the formation of viral 
antigens (4). 
The present paper reports evidence that the administration of helenine is fol- 
lowed by the formation in cultures of L-929 cells, or in intact mice, of an in- 
hibitor of viral replication which fulfills the major biological and physicochemi- 
cal criteria for interferon. 
* This investigation was supported in part  by Public Health Service Research Grant 
AI-01595 and Training Grant 5-TIAI 6 from the National Institutes of Allergy  and Infectious 
diseases, Bethesda, Maryland. 
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Materials and Methods 
Tissue  Cul~re.--L-929  cells  (NCTC  clone 929)  were  obtained  from  the  South  Jersey 
Medical Research  Foundation,  Camden,  New ~ersey,  and  grown in  250  ml plastic  flasks 
(Falcon Plastic Company, Los Angeles) in medium 199 fortified with 5% heat-inactivated calf 
serum, in the presence of penicillin (100 units/ml) and streptomycin (100/~g/ml).  The cells 
were then resuspended for transfer by trypsinization (trypsin 0.05%,  Difco Laboratories, Inc., 
Detroit). Repeated testing failed to demonstrate pleuropneumonialike organisms (PPLO). 
Virus.--Vesicular stomatitis virus (VSV)  (Indiana strain) served as the indicator virus in 
interferon titrations.  In order to obtain plaques of uniform size, which would facilitate the 
assessment of plaque number, the seed virus was isolated by plaque purification and propa- 
gated in L-929 cells. Titers in the order of 107/0.2 ml were uniformly obtained. In interferon 
fitrafions the seed virus was diluted in medium 199 with 0.1% bovine albumin to give ap- 
proximately 50 plaque-forming units (PFU)/0.2 ml. 
Animals.--Male  mice of the MF-1 pathogen-free strain  (supplied by the Manor Farms, 
Staatsburg, New York) were chosen for use to insure a greater uniformity of response and to 
reduce the possibility of endogenous infections, since it has been demonstrated that certahi 
bacteria can elicit the formation of interferonlike substances  (6).  In every experiment, mice 
8 to 9 wk of age were employed, weighing on the average 32 to 36 g. At the beginning of each, 
the mice were placed in individual cages. 
ttdenine.--Several  lots of helenine were employed. They were prepared  from broth cul- 
tures of Pen~illium ]uniculosum according to the methods described previously (1).  When 
tested for protection against  viral challenge, they were found to be uniformly effective in 
that  all pretreated  mice survived subcutaneous  challenge with  10  to  1000  lethal doses of 
Semliki Forest virus whereas all untreated mice succumbed. The helenine preparations were 
stored at -20°C until ready to use at which time they were quick-thawed (and subsequently 
stored at 4°C). 
Induvtion o] the Inhibitor in Tissue Culture.--When  a  complete monolayer (consisting of 
approximately 107 cells) was established in a 250 ml plastic flask, growth medium was removed 
and  1.0 ml of undiluted helenine added. A control flask was similarly treated with No. 199 
maintenance medium. The bottles were incubated at 37°C for 30 rain to permit absorption of 
helenine and  then 20 ml of medium  199 was added to each bottle and incubation at 37°C 
resumed. 24 hr later the tissue culture fluids were harvested and sterility tests carried out in 
sheep blood agar and thioglycollate broth. 
lnduvtion of the Inhibitor in Mice.--Mice  were injected into the tail vein with 0.2  or 0.5 
ml of undiluted helenine or, for control purposes, with equal amounts of saline, utilizing 1 ml 
syringes and 26 gauge, IN inch disposable needles. Bloods were collected from groups of 6 
mice at  indicated  time intervals,  under  nembutal  anesthesia,  by  cardiac  puncture.  After 
clotting, the sera were separated by centrifugation and  stored at 4°C. Organ extracts were 
prepared  by homogenizing pooled organs as  10%  (by wet weight)  suspensions  in  medium 
199 with 0.1% bovine albumin and they were clarified by centrifugation at 10,000 m,~ for 10 
rain in a Lourdes centrifuge. 
Titration of the Inhibitor.--Inhibitor  titration was carried out according to a modification 
of Wagner's 50% plaque reduction method of interferon assay (7). L-929 cells were grown in 
medium 199 with 5% inactivated calf serum and antibiotics in 60 mm plastic dishes (Falcon). 
The dishes were seeded with 0.5 X  106 cells each and incubated in a 5% CO2 atmosphere at 
37°C.  Complete monolayers were achieved in 48 hr.  Specimens consisting of sera,  organ ex- 
tracts, or tissue culture fluids were serially diluted by 2- or 4-fold in medium 199 with 0.1% 
bovine albumin. Cell monolayers were then overlaid with 2 ml aliquots of the diluted samples 
and incubated at 37°C for 6 hr. Then these fluids were removed, monolayers were washed 
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mated 50 PFU of VSV. After 30 rain absorption at 37°C, 5 mi of 1% agar (Ionagar, Oxoid 
Division,  Consolidated Laboratories,  Chicago Heights,  Illinois) with  medium  199  and  1% 
heat-inactivated  calf serum was added and the dishes were reincubated for 48 hr.  At that time 
the cell monolayers were stained with neutral  red  (0.02%) in medium 199 for 3 hr and  the 
plaques were counted. 
The fiter of the inhibitor  was taken as the reciprocal of the highest  dilution giving 50% 
reduction in the plaque number, as compared with the control number, and expressed in terms 
of units per 2 ml. When the desired degree of plaque reduction fell between two dilutions, the 
titer was determined  by interpolation.  In replicate titmtlons of the same sample, the titers 
did not differ by more than 2-fold, in most instances. 
TABLE I 
Produaion of InterJeronl~ke Viral Inhibitor in L.-gg9 Cell Cultures with Helenine 
Inhibitor concentrations* 
Cell culture 
Experiment 1  Experiment 2 
Helenine-treated  160  178 
Control~  0  0 
* Units of interferon per 2 ml of cell culture fluid collected 24 hr following administration 
of helenine. 
~: Treated with No. 199 maintenance  medium. 
RESU'LTS 
Induction of the Ink~tor in Tissue Culture.--When helenine was added to a 
monolayer of L-929 cells in a flask (as described above), and the tissue culture 
fluid obtained  24 hr later was assayed,  an inhibitor fiter of 160 units was ob- 
tained in one experiment. In another, the inhibitor titer was 178 units. The con- 
trol fluids had no inhibitory activity (Table I). 
Induction of the Inkibitor in Mice.--In a preliminary experiment, a serum pool 
from a  group of 6 mice inoculated 16 hr previously with 0.2 ml of helenine was 
found to have an inhibitor titer of 538 units, whereas pooled control serum had 
no inhibitory activity at a dilution of 1/4. 
In order to determine the kinetics of the appearance of inhibitor in the serum, 
the following experiment was conducted. 
Groups of 6 mice were injected into the tail vein with 0.2 ml of helenine and 
serum samples were collected at 2, 6, 12, 16, 24, and 48 hr. Control groups which 
received saline were bled at 6 and 24 hr after injection. 
The experimental results of these tests are summarized in Table II. Inhibitor 
appeared at 2 hr, was demonstrable for 24 hr, but none was present after 48 hr. 
The highest levels were obtained at 12 and 16 hr when the titer was 630 units. 
Control sera showed no inhibitory activity at a dilution of 1/4. 
The Effect of Different Doses of Helenine on the Formation of the Inkibitor.-- 
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lated intravenously into mice, progressively greater amounts of inhibitor were 
demonstrable  16 hr later. The highest response, corresponding  to  1994  units, 
was achieved with the 0.5 mi dosage (Table III). One tenth of this dose (0.05 ml) 
of helenine resulted in an inhibitor level of 10 units. The dose of 0.2 ml employed 
in most experiments resulted in a  titer of 600 units.  These data, though pre- 
liminary, provide evidence for a dose-effect curve with helenine administration. 
TABLE II 
Kinetics of Formation of Interferonllke Viral Inhibitor in Sera of Mice Following Intravenous 
Injection of Hdenine 
Time after injection 
hr 
2 
6 
12 
16 
24 
48 
Inhibitor concentrations* 
Helenine injected 
unlts/g n;l 
12 
256 
630 
630 
64 
0 
Saline injected 
units/g nd 
0 
0 
* Pooled sera from 6 mice in each group. 
TABLE  III 
Effect of Administration of Different Amounts  of ttdenine on tke Levds of Serum Inhibitor 
Collected 16 Hr Later 
Amount of helenine  Inhibitor concentrstions 
ml 
O* 
0.05 
0.2 
0.5 
units/2mt 
0 
10 
600 
1994 
* Given 0.2 ml saline. 
Inhibitor Concentrations in Tissue Extracts.--Repeated  attempts were made 
to determine the presence of the inhibitor in tissue extracts from mice injected 
with helenine. When 10 % homogenates of spleen, lung, and liver, obtained at 6 
and 16 hr after injection of helenine, were assayed, there was a decrease in the 
plaque size and number at the lowest dilutions (1/4 and 1/8), the greatest de- 
crease occurring with the splenic extracts.  The degree of plaque suppression, 
however, was only slightly greater than that obtained with extracts from con- 
trol animals. The inhibitor concentrations in the pooled sera from these animals 
were 112 units at 6 hr and 278 units at 16 hr. 
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Newcastle  disease  virus  (NDV)  as  interferon-inducer  in  mice,  comparable 
tissue homogenates did contain significant amounts of interferon. Since much 
higher  serum interferon concentrations were  achieved in  these  experiments, 
however, it is felt that the borderline amounts of interferon found in tissue ex- 
tracts in the present study may merely represent variations in the degree of in- 
terferon stimulation by the two different inducers.  Altematively other sites, 
such as lymph nodes, which were not examined in the present study, may be the 
main sites of the interferon formation induced by helenine. 
Physicochemical  and  Biological  Characterization  of the  Helenine-Induced  In- 
hibitor.--A  number  of studies were  conducted in  order  to  determine if the 
helenine-induced inhibitor, either as found in tissue culture or in the sera of 
mice, fulfilled the basic criteria for the definition of interferon (Table IV). The 
TABLE IV 
The Physicochemical Properties of Interferonlike Inhibitor Induced by Hdenine in L-999 Cell 
Cultures and in Mice 
Treatment of specimens 
Untreated 
Dialysis against pH 2/24 hr 
Centrifugation at 105,000 g/2 hr 
Heating at 56  ° C/30 rain 
Treatment with trypsin 500 ~g/ml at 37 ° C/60 rain 
Inhibitor concentrations 
Cell culture  Mouse sera  preparations 
unils/2 ml  un~ls/Zml 
170  270 
178  128 
105  256 
8  8 
0  0 
inhibitor was shown to be  acid-stable  and nondiallzable on dialysis  at  4°C 
against a pH 2.0 glycine buffer for 24 hr, followed by dialysis for 24 hr against a 
pH 7.2 phosphate buffer (to restore neutrality). It was completely inactivated 
when incubated with 500 #g/ml of crystalline trypsin for 1 hr at 37°C.  It did 
not sediment when centrifuged at 105,000 g for 2 hr. It was almost completely 
inactivated by incubation at 56°C for 30 min, as has been reported previously 
for mouse interferon both in  tissue culture  (8)  and serum preparations  (6). 
When titrated in a  cell line derived from a heterologous species,  i.e., a  human 
conjuncfival cell variant (clone 1-5C-4) (10), it had no inhibitory effect. Finally, 
the inhibitor was not directly virucidal as indicated by the absence of any de- 
crease in plaque-forming units  when VSV  was incubated either  with  tissue 
culture or serum preparations. 
DISCUSSION 
From all of the data that have been presented, it is concluded that the in- 
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A number of nonviral substances have been shown to be capable of inducing 
interferonlike inhibitors. These include phytohemaggiutinin (11),  bacteria and 
bacterial endotoxins (6),  nucleic acids of viral and nonviral origins (12),  and 
statolon, a substance derived from Penicillium stoloniferum  (13, 14). 
Studies on these nonviral but virus-inhibiting interferons have revealed that 
some of them differ in several important respects from the "classical" interferon 
induced by viruses. For example, interferon formed in response to endotoxin 
can only be called forth in an intact animal, not in tissue culture, it has a higher 
molecular weight, 85,000 to 89,000 compared to 25,000 to 31,000 for most viral 
interferons (15),  and it is demonstrable in peak titer 2 hr after endotoxin ad- 
ministration but is almost undetectable by 12 hr (6).  Statolon-induced inter- 
feron, on the other hand, possesses  most of the characteristics of viral inter- 
feron in that it can be produced both in tissue culture (13) and in vivo systems 
(14);  the kinetics of its appearance in the serum are similar to those of viral 
interferon and its molecular weight when produced in tissue culture is similar 
to that of NDV-induced tissue culture interferon (14).  The serum interferon 
induced by statolon, however, does differ from virus-induced interferon in hav- 
ing an apparent molecular weight of 90,000 (14). 
Interferon induced by helenine, like that induced by statolon, possesses  most 
of the characteristics of virus-induced interferon. The kinetics of its appearance 
in the serum follow those of NDV-induced interferons in that a maximum titer 
appears in 12 hr (6, 9). No information is yet available, however, on its molecu- 
lar weight or on the effect of such inhibitors as actinomycin D on its formation. 
The active principle in helenine is still a matter of conjecture since it has not 
been obtained in a  sufficiently pure form to permit  definite identification. Ac- 
cording to previous analysis, preparations of helenine contain both  nucleopro- 
teins  (16)  and  polysaccharides  (17),  both  of  which  have  been  shown  to 
be capable of inducing interferon formation (12, 13, 6). 
Because of technical difficulties incidental to production of interferon of hu- 
man origin in sufficient amounts, prospects for prophylactic and therapeutic 
trials with exogenous interferon are not good at the present time. It has been 
suggested that a possible clinical approach may be through induction of endoge- 
nous interferon in man (18). In this relation, substances like helenine may hold 
great promise. 
SUMMARy 
Helenlne, a  substance obtained from broth cultures of Penicillium funiculo- 
sum and known to exert a  protective effect in vivo in experimental animals 
against several unrelated viruses, has been shown to elicit the formation in cell 
cultures and in intact mice of an inhibitor of viral plaque formation. 
Because the biological and chemical characteristics of the viral inhibitor in- M.  Wo  RYTEL, R.  E.  SHOPE~ AND E.  D.  KILBOURNE  583 
duced by helenine are similar to those of interferon, it is suggested that the anti- 
viral effect of helenine may be mediated through the formation of interferon. 
The authors would like to acknowledge  with gratitude the valuable technical assistance 
rendered by Miss Efleen Brady. 
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